Patents by Inventor Jacqulyne ROBICHAUX

Jacqulyne ROBICHAUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS
    Publication number: 20230233563
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
    Type: Application
    Filed: August 24, 2022
    Publication date: July 27, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
  • USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
    Publication number: 20230121116
    Abstract: Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti-HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti-HER2/HER3 antibodies.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 20, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX
  • USE OF EGFR/HER2 TYROSINE KINASE INHIBITORS AND/OR HER2/HER3 ANTIBODIES FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
    Publication number: 20230112470
    Abstract: Provided herein are methods of selecting cancer patients for treatment with a covalent EGFR/HER2 TKI, a HER2/HER3 targeting antibody, or a combination of a covalent EGFR/HER2 TKI and a HER2/HER3 targeting antibody as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with a covalent EGFR/HER2 TKI, a HER2/HER3 targeting antibody, or a combination of a covalent EGFR/HER2 TKI and a HER2/HER3 targeting antibody.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 13, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX
  • USE OF POZIOTINIB FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
    Publication number: 20230069749
    Abstract: Provided herein are methods of selecting cancer patients for treatment with poziotinib as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with poziotinib alone or in combination with HER2/HER3 targeting antibodies.
    Type: Application
    Filed: January 29, 2021
    Publication date: March 2, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX
  • Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
    Patent number: 11446302
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 20, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jacqulyne Robichaux, Monique Nilsson, John V. Heymach
  • COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS
    Publication number: 20220193074
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a second-generation quinazolinamine derivative tyrosine kinase inhibitor.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 23, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
  • HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
    Publication number: 20220194940
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 23, 2022
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX, Monique NILSSON, Philip JONES, Jason CROSS, Jay THEROFF
  • Heterocyclic inhibitors of tyrosine kinase
    Patent number: 11365189
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: June 21, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: John Heymach, Jacqulyne Robichaux, Monique Nilsson, Philip Jones, Jason Cross, Jay Theroff
  • COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 21 INSERTIONS
    Publication number: 20220175778
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an HER2 exon 21 mutation by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, John V. HEYMACH
  • COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS
    Publication number: 20220175779
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.
    Type: Application
    Filed: April 16, 2020
    Publication date: June 9, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
  • COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 INSERTIONS
    Publication number: 20220143023
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 12, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH
  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220041751
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a HER2 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib, in combination with a HER2 anti-body-drug conjugate.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 10, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: John V. HEYMACH, Jacqulyne ROBICHAUX, Monique NILSSON
  • COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 19 MUTATIONS
    Publication number: 20210361655
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a HER2 exon 19 mutation, such as a point mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.
    Type: Application
    Filed: March 27, 2019
    Publication date: November 25, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, John V. HEYMACH
  • METHODS FOR TREATMENT OF CANCERS WITH EGFR ACTIVATING MUTATIONS
    Publication number: 20210015819
    Abstract: The present disclosure provides methods for treating cancer in a patient determined to have an EGFR activating mutation by administering a CDK inhibitor and/or SAC component inhibitor.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 21, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: John V. HEYMACH, Monique NILSSON, Jacqulyne ROBICHAUX
  • HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
    Publication number: 20200354343
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 12, 2020
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX, Monique NILSSON, Philip JONES, Jason CROSS, Jay THEROFF
  • COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS
    Publication number: 20200316071
    Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 8, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jacqulyne ROBICHAUX, Monique NILSSON, John V. HEYMACH